AIDS |
acquired immunodeficiency syndrome |
BATTLE |
Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination |
BRAF |
Rapidly Accelerated Fibrosarcoma (B family) |
CaBIG |
cancer Biomedical Informatics Grid |
CDER |
Center for Drug Evaluation and Research |
CDRH |
Center for Devices and Radiological Health |
CEO |
chief executive officer |
CGL |
chronic granulocytic leukemia |
CITN |
Cancer Immunotherapy Trials Network |
CMS |
Center for Medicare & Medicaid Services |
CRADA |
Cooperative Research and Development Agreement |
CTEP |
Cancer Therapy Evaluation Program |
CTLA-4 |
Cytotoxic T-Lymphocyte Antigen 4 |
DCE-MRI |
dynamic contrast enhanced-magnetic resonance imaging |
DOJ |
Department of Justice |
EGFR |
epidermal growth factor receptor |
EMA |
European Medicines Agency |
ER |
estrogen-receptor |
FDA |
Food and Drug Administration |
FNIH |
Foundation for the National Institutes of Health |
FTC |
Federal Trade Commission |
GSK |
GlaxoSmithKline |
HER2 |
human epidermal growth factor receptor 2 |
HIV |
Human Immunodeficiency Virus |
HPV |
human papillomavirus |
IGF |
insulin-like growth factor |
IIP |
instantaneous inhibitory potential |
IND |
Investigational New Drug |
IP |
intellectual property |
IRB |
Institutional Review Board |
I-SPY TRIAL |
Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis |
LCMV |
lymphocytic choriomeningitis virus |
MAPK |
mitogen-activated protein kinase |
MEK |
mitogen-activated protein kinase kinase |
MET |
Methylnitronitrosoguanidine-HOS (Human osteosarcoma) Transforming gene |
MTA |
Material Transfer Agreement |
mTORC1 |
mammalian target of rapamycin complex-1 |
NCDDG |
National Cooperative Drug Discovery Groups |
NCI |
National Cancer Institute |
NERF |
non-exclusive royalty-free |
NIAID |
National Institute of Allergy and Infectious Diseases |
NIH |
National Institutes of Health |
NOD |
non-obese diabetic |
OS |
overall survival |
PathCR |
pathological complete response |
PET |
positron emission tomography |
PFS |
progression-free survival |
PI3K |
phosphatidylinositol 3-kinase |
PPTP |
Pediatric Preclinical Testing Program |
R&D |
research and development |
SOC |
standard of care |
START |
Standard Terms of Agreement for Research Trial |
VEGF |
vascular endothelial growth factor |